Format

Send to

Choose Destination
Clin Cancer Res. 2016 Jun 1;22(11):2599-601. doi: 10.1158/1078-0432.CCR-16-0100. Epub 2016 Mar 15.

Is There a Future for AKT Inhibitors in the Treatment of Cancer?

Author information

1
Breast Cancer Program, Vanderbilt-Ingram Cancer Center (VICC), Vanderbilt University, Nashville, Tennessee.
2
Breast Cancer Program, Vanderbilt-Ingram Cancer Center (VICC), Vanderbilt University, Nashville, Tennessee. carlos.arteaga@vanderbilt.edu.

Abstract

An AKT inhibitor plus an antiestrogen exhibited no significant clinical activity in patients with ER(+)/HER2(-) breast cancer despite laboratory studies supporting an antitumor effect for both drugs combined. These results raise concerns about the development of AKT inhibitors in unselected patients whose tumors have unknown dependence on the PI3K/AKT pathway. Clin Cancer Res; 22(11); 2599-601. ©2016 AACRSee related article by Ma et al., p. 2650.

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center